Approved by President Xi Jinping, a 30-person national ethics committee has been appointed in China to oversee high-risk clinical trials, STAT News reported. The technologies that will be monitored and regulated are considered risky due to moral or safety concerns and include gene editing, cloning, cell therapy, xenotransplantation, mitochondrial replacement, and nanotechnology. Oversight of these medical technologies aims to counter the perception of weak ethics governance many believe led to the controversial “CRISPR babies” program.
https://www.statnews.com/2019/03/05/china-creating-national-medical-ethics-committee/